Citius Pharmaceuticals (CTXR)
NASDAQ:CTXR
Top Page
Citius Pharmaceuticals
(NASDAQ:CTXR)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.67
▼(-21.74% Downside)
Action:ReiteratedDate:04/01/26
The score is held back primarily by large ongoing losses and significant cash burn, reinforced by weak technical momentum. Offsetting factors include a low-debt balance sheet and positive LYMPHIR-related corporate updates indicating early commercial traction and encouraging Phase 1 signals, but valuation support is limited given negative earnings.
Positive Factors
Low leverage / balance sheet flexibility
Very low debt and meaningful equity provide durable financial flexibility for a clinical-stage biotech. With minimal leverage the company can pursue clinical programs, commercial rollouts, or partnerships without onerous interest burdens, reducing bankruptcy risk versus highly levered peers.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow of roughly $35M TTM indicates the company cannot self-fund development and commercialization long-term. Continued cash burn necessitates external financing, constraining runway and forcing strategic trade-offs in R&D and commercial investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet flexibility
Very low debt and meaningful equity provide durable financial flexibility for a clinical-stage biotech. With minimal leverage the company can pursue clinical programs, commercial rollouts, or partnerships without onerous interest burdens, reducing bankruptcy risk versus highly levered peers.
Read all positive factors
Citius Pharmaceuticals (CTXR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.01M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)2.22
Revenue GrowthN/A
EPS Growth18.73%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding22,376,427
10 Day Avg. Volume511,305
30 Day Avg. Volume1,160,981
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.52
Enterprise Value/Market Cap0.18
Enterprise Value/Revenue0.82
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.9
Revenue Forecast (FY)$78.00M
Citius Pharmaceuticals Business Overview & Revenue Model
Company Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem ce...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Citius Pharmaceuticals’ business model has historically centered on advancing product candidates through development and regulatory pathways rather than generating recurring revenue from an establishe...
Citius Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.42M | -214.25K | -209.61K | -194.32K | -179.68K | -164.87K |
| EBITDA | -36.68M | -38.20M | -38.64M | -31.77M | -32.88M | -22.88M |
| Net Income | -35.89M | -37.43M | -39.14M | -32.54M | -33.64M | -23.13M |
Balance Sheet | ||||||
| Total Assets | 140.39M | 130.94M | 116.65M | 103.61M | 114.00M | 142.43M |
| Cash, Cash Equivalents and Short-Term Investments | 7.72M | 4.25M | 3.25M | 26.48M | 41.71M | 70.07M |
| Total Debt | 1.83M | 1.81M | 262.87K | 481.25K | 678.23K | 855.47K |
| Total Liabilities | 46.92M | 53.41M | 42.55M | 12.18M | 10.57M | 9.65M |
| Stockholders Equity | 79.96M | 67.55M | 70.08M | 90.83M | 102.83M | 132.18M |
Cash Flow | ||||||
| Free Cash Flow | -34.84M | -26.55M | -28.20M | -29.06M | -28.36M | -64.26M |
| Operating Cash Flow | -34.84M | -26.55M | -28.20M | -29.06M | -28.36M | -24.25M |
| Investing Cash Flow | -10.15M | -5.75M | -5.00M | 0.00 | 0.00 | -40.01M |
| Financing Cash Flow | 51.61M | 33.30M | 9.97M | 13.83M | 0.00 | 120.47M |
Citius Pharmaceuticals Technical Analysis
Neutral
0.86
Price Trends
0.79
Positive
0.90
Negative
1.15
Negative
Market Momentum
<0.01
Negative
51.16
Neutral
52.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Neutral. The current price of 0.86 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 0.79, and below the 200-day MA of 1.15, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.16 is Neutral, neither overbought nor oversold. The STOCH value of 52.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CTXR.
Citius Pharmaceuticals Risk Analysis
Citius Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Citius Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Citius Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $31.73M | -0.82 | -87.18% | ― | ― | 38.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $18.01M | -0.51 | -54.40% | ― | ― | 18.73% | |
48 Neutral | $29.18M | -1.88 | >-0.01% | ― | -12.99% | -13.67% | |
40 Underperform | $7.31M | -13.72 | -27.54% | ― | -100.00% | 93.62% |
* Healthcare Sector Average
CTXR
Citius Pharmaceuticals
0.82
-0.17
-17.59%
SYBX
Synlogic
0.62
-0.48
-43.64%
MRKR
Marker Therapeutics
1.74
0.64
58.18%
HOTH
Hoth Therapeutics
0.51
-0.31
-37.68%
PASG
Passage Bio
10.81
3.15
41.12%
Citius Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Citius Oncology advances LYMPHIR launch and global expansion
Positive
Apr 1, 2026
On March 31, 2026, Citius Oncology reported early commercial progress for LYMPHIR’s U.S. launch in CTCL, citing strong institutional uptake, repeat orders, and approximately 135 health plans providing coverage representing about 80% of cover...
Business Operations and StrategyProduct-Related Announcements
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data
Positive
Mar 10, 2026
On March 10, 2026, Citius Oncology reported positive topline results from an investigator-initiated Phase 1 trial led by the University of Pittsburgh evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or refractory gyn...
Business Operations and StrategyProduct-Related Announcements
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data
Positive
Mar 4, 2026
On March 4, 2026, Citius Oncology reported positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsRegulatory Filings and Compliance
Citius Pharmaceuticals Posts First Revenue Amid Listing Risk
Neutral
Feb 13, 2026
On February 9, 2026, Citius Pharmaceuticals received notice that its Nasdaq-listed common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance or face potential...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.